# UCSD study links teen cannabis use to slower cognitive development, researchers weigh risks > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/teen-cannabis-use-cognitive-development-ucsd-study-analysis/ > **Published:** 2026-05-18T19:58:37-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T09:54:53-04:00 > **Clinical Summary:** UCSD study examines teen cannabis use cognitive development links. Dr. Caplan analyzes research findings and clinical implications for adolescent brain health. --- CED Clinical Relevance  #60Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Adolescent MedicineNeurodevelopment[Cognitive Function](https://cedclinic.com/reverse-cholesterol-transport-function-cannabis-users/)Risk AssessmentTeen Health Why This Matters [Adolescent brain development](https://cedclinic.com/adolescent-cb1-receptor-antagonism-social-behavior/) continues through the mid-20s, making this population particularly vulnerable to substance-related cognitive impacts. Any evidence linking cannabis use to developmental delays in teens directly informs clinical counseling and risk-benefit discussions with young patients and families. Clinical Summary A UCSD study appears to demonstrate an association between [adolescent cannabis use](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) and slower cognitive development, though specific details about study design, duration, and magnitude of effects are not provided in this summary. The adolescent brain undergoes significant maturation in areas including executive function, working memory, and decision-making through approximately age 25. Cannabis affects the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/), which plays a role in neurodevelopment, though the precise mechanisms and reversibility of any cognitive effects remain areas of active research. Dr. Caplan’s Take “While I need to see the actual study methodology and effect sizes, any credible evidence of developmental impact in teens reinforces what I tell families: the adolescent brain is still under construction, and we should be extremely cautious about introducing any psychoactive substance during this critical period.” Clinical Perspective 🧠 Clinicians should continue emphasizing delayed initiation of cannabis use whenever possible, particularly for patients under 21. This reinforces existing clinical guidance about brain development vulnerability. However, for teens with severe medical conditions where cannabis may be indicated, the risk-benefit analysis remains individualized and requires careful monitoring with families. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20UCSD%20study%20links%20teen%20cannabis%20use%20to%20slower%20cognitive%20development%2C%20researchers%20...%20%40drcaplan&url=https%3A//ucsdguardian.org/2026/04/27/ucsd-study-links-teen-cannabis-use-to-slower-cognitive-development-researchers-weigh-risks/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//ucsdguardian.org/2026/04/27/ucsd-study-links-teen-cannabis-use-to-slower-cognitive-development-researchers-weigh-risks/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20UCSD%20study%20links%20teen%20cannabis%20use%20to%20slower%20cognitive%20development%2C%20researchers%20...%20--%20via%20%40drcaplan.bsky.social%20https%3A//ucsdguardian.org/2026/04/27/ucsd-study-links-teen-cannabis-use-to-slower-cognitive-development-researchers-weigh-risks/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://ucsdguardian.org/2026/04/27/ucsd-study-links-teen-cannabis-use-to-slower-cognitive-development-researchers-weigh-risks/](https://ucsdguardian.org/2026/04/27/ucsd-study-links-teen-cannabis-use-to-slower-cognitive-development-researchers-weigh-risks/) Table of Contents - [FAQ](#FAQ)[What age group is most at risk for cannabis-related neurodevelopmental effects?](#What_age_group_is_most_at_risk_for_cannabis-related_neurodevelopmental_effects) - [How does cannabis use affect cognitive function in teenagers?](#How_does_cannabis_use_affect_cognitive_function_in_teenagers) - [What should healthcare providers assess when evaluating teen cannabis use?](#What_should_healthcare_providers_assess_when_evaluating_teen_cannabis_use) - [Are the effects of adolescent cannabis use reversible?](#Are_the_effects_of_adolescent_cannabis_use_reversible) - [What makes this research clinically significant for pediatric providers?](#What_makes_this_research_clinically_significant_for_pediatric_providers) - [Related](#Related) ## FAQ #### What age group is most at risk for cannabis-related neurodevelopmental effects? Adolescents and young adults are at highest risk since their brains are still developing until approximately age 25. The adolescent brain is particularly vulnerable to the effects of THC and other [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) during this critical developmental period. #### How does cannabis use affect cognitive function in teenagers? Cannabis use during adolescence can impair memory, attention, learning capacity, and executive function. These cognitive effects may persist even after stopping use, particularly in heavy or frequent users who started during their teen years. #### What should healthcare providers assess when evaluating teen cannabis use? Providers should conduct comprehensive risk assessments including frequency of use, age of first use, academic performance, and mental health status. Early identification and intervention are crucial for preventing long-term neurodevelopmental consequences. #### Are the effects of adolescent cannabis use reversible? Some cognitive effects may improve with prolonged abstinence, but certain neurodevelopmental impacts can be long-lasting or permanent. The extent of recovery depends on factors like duration of use, frequency, potency, and individual biological factors. #### What makes this research clinically significant for pediatric providers? This represents emerging evidence that should inform clinical practice and patient counseling about cannabis risks in adolescents. Healthcare providers need current data to effectively communicate risks and develop appropriate prevention and intervention strategies for young patients. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).